Published in Carcinogenesis on April 18, 2016
Y-family DNA polymerase-independent gap-filling translesion synthesis across aristolochic acid-derived adenine adducts in mouse cells. DNA Repair (Amst) (2016) 0.75
Balkan endemic nephropathy: an update on its aetiology. Arch Toxicol (2016) 0.75
Cancer genome landscapes. Science (2013) 25.33
Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) N Engl J Med (2000) 8.02
Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet (1993) 6.56
Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A (2007) 2.52
Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med (2013) 2.30
Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int (2011) 2.28
Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med (2013) 2.07
Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int (2008) 1.86
Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A (2012) 1.82
Aristolochic acid nephropathy in a Chinese patient: time to abandon the term "Chinese herbs nephropathy"? Am J Kidney Dis (2001) 1.61
Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact (2000) 1.53
Identification of aristolochic acid in Chinese herbs. Lancet (1994) 1.45
Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? Kidney Int (2001) 1.43
Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie". Drug Metab Dispos (2009) 1.38
Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int (1994) 1.38
Inhibition of sulfotransferases by xenobiotics. Curr Drug Metab (2006) 1.29
DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res (2009) 1.23
Tumour induction in mice following exposure to aristolochic acid. Arch Toxicol (1988) 1.21
Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen (2012) 1.20
Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res (2011) 1.20
Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun (2014) 1.17
Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy. Kidney Int (2012) 1.15
Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug Metab Dispos (2006) 1.12
Acute nephrotoxicity of aristolochic acids in mice. J Pharm Pharmacol (2004) 1.12
Selective toxicity of aristolochic acids I and II. Drug Metab Dispos (2007) 1.11
Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr Drug Metab (2006) 1.07
Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities. Nat Prod Rep (2003) 1.03
Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res (1990) 1.02
Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis (1990) 1.02
Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr Opin Drug Discov Devel (2009) 1.01
Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int J Cancer (2006) 1.01
32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis (1990) 0.97
Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab Dispos (2010) 0.97
Comparison of DNA adduct formation by aristolochic acids in various in vitro activation systems by 32P-post-labelling: evidence for reductive activation by peroxidases. Carcinogenesis (1997) 0.96
Studies on the metabolism of aristolochic acids I and II. Xenobiotica (1987) 0.95
The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ Mol Mutagen (2011) 0.93
Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2006) 0.91
Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int J Cancer (2010) 0.91
Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis (2002) 0.89
mRNA expression of multiple cytochrome p450 isozymes in four types of cultured skin cells. Int Arch Allergy Immunol (2002) 0.88
Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer. Curr Drug Metab (2013) 0.88
Mutagenicity of the two main components of commercially available carcinogenic aristolochic acid in Salmonella typhimurium. Cancer Lett (1984) 0.87
Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity. Toxicol Sci (2011) 0.84
Quantification of aristolochic acids I and II in herbal dietary supplements by ultra-high-performance liquid chromatography-multistage fragmentation mass spectrometry. Food Addit Contam Part A Chem Anal Control Expo Risk Assess (2014) 0.83
Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis (2014) 0.83
The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats. Mutagenesis (2014) 0.80
The metabolic activation of nitroheterocyclic therapeutic agents. Drug Metab Rev (1988) 0.80
Cd²⁺-induced alteration of the global proteome of human skin fibroblast cells. J Proteome Res (2014) 0.80
Total synthesis of the aristolochic acids, their major metabolites, and related compounds. Chem Res Toxicol (2014) 0.78
Recent studies on the metabolic activation of chemical carcinogens. Cancer Res (1994) 0.76
Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis (2014) 0.83